Sunzen Group Berhad (“Sunzen” or “the Group”), formerly known as Sunzen Biotech Berhad and an established player in Malaysia’s health products, medical devices and services, and loan financing with a diversified portfolio, announced its results for the quarter ended 30 June 2025 (“Q4 FY2025”), posting RM14.98 million in revenue.
This brought the Group’s revenue for the full financial year ended 30 June 2025 (“FYE2025”) to RM80.98 million, supported by sustained contributions from its Loan Financing and Human Health segments, as well as continued growth from Medical Devices and Services.
Despite the solid topline performance, the Group recorded a pre-tax loss of RM0.53 million in Q4 FY2025, largely due to a one-off bad debt write-off of RM2.97 million within the Loan Financing division, as well as weaker profitability from the Human Health segment and loss stem from an associate company.
Nevertheless, Sunzen concluded FYE2025 with a profit before tax (“PBT”) of RM5.15 million.
As the Group had changed its financial year-end from 31 December to 30 June in 2024, there are no corresponding year-on-year (“YoY”) comparisons available.
The Loan Financing division remained a significant earnings contributor, posting RM4.15 million in revenue and RM0.82 million in PBT for Q4. For the full year, the segment delivered RM14.14 million in revenue and RM9.84 million in PBT.
While the one-off impairment affected quarterly results, the underlying business remains strong, supported by a healthy loan pipeline and continued demand.
Sunzen’s newest business segment, acquired in October 2024, continued to gain traction. It contributed RM2.05 million in revenue and RM0.43 million in PBT for the quarter under review, bringing full-year revenue to RM6.96 million and PBT to RM1.26 million.
The segment is expected to play an increasingly prominent role in the Group’s earnings profile, driven by rising demand for ophthalmic medical products and new product launches.
The Human Health segment registered RM8.79 million in revenue for Q4, resulting in RM57.08 million for the full year. However, the segment posted a pre-tax loss of RM0.87 million in the quarter, primarily due to reduced export and domestic sales, as well as margin compression.
This brought the segment’s full-year loss before tax to RM1.56 million. While bird’s nest exports to China resumed in January 2025 following regulatory clearance, overall market sentiment remains weak amid subdued consumer spending.
Notably, the Group has fully exited the Animal Health segment following the completion of its divestment. No revenue was recorded in Q4, although the segment posted a loss of RM0.91 million due to winding down costs and intra-group adjustments.
Compared on a quarterly basis, the Group’s revenue declined slightly by 4.49% from RM15.69 million in the preceding quarter to RM14.98 million in Q4 FY2025, mainly due to lower sales in the Human Health segment and loss stem from an associate company.
The Group swung to a pre-tax loss of RM0.53 million from a profit of RM1.92 million in Q3, reflecting the impact of the bad debt provision in the Loan Financing segment.
Group Managing Director of Sunzen Group Berhad, Mr. Teo Yek Ming commented,
“While our fourth quarter was impacted by exceptional items, our core businesses remain solid. The continued growth from our Medical Devices and Services segment and healthy momentum in loan financing provide a strong base to build on. We will continue to allocate resources toward expanding high-potential segments while improving operational efficiencies in the Human Health segment.”
Looking ahead, the Group anticipates steady growth in its Loan Financing division, supported by increasing applications and approvals. Efforts are underway in the Human Health segment to reposition product offerings toward the fast-moving consumer goods (“FMCG”) market, including the repackaging of Bird’s Nest drink into polypropylene (“PP”) bottles and increased brand visibility through digital marketing and trade fairs. Expansion into Original Design Manufacturing (“ODM”) services is also underway to reduce reliance on Original Equipment Manufacturing (“OEM”) customers.
Despite ongoing softness in the China bird’s nest market due to cautious consumer sentiment, Sunzen continues to innovate with Yanming’s new Quantum Therapy equipment for blood circulation and metabolism, complemented by a herbal cream transdermal delivery system to promote wellness.
In the Medical Devices and Services segment, Sunzen is preparing to introduce new product lines, including intraocular lens (“IOL”) with Toric variants, while capitalising on demand for equipment sales and diagnostic services.
For more information, visit www.sunzengroup.com
